Daewoong Pharmaceutical has topped 1 trillion won ($688 million) in outpatient prescription sales for the second straight year in 2024, driven by rapid growth in its gastroesophageal reflux treatment Fexuclue (fexuprazan) and diabetes drug Envlo (enavogliflozin). 

According to UBIST data, the Korean drugmaker recorded 1.03 trillion won in outpatient prescription sales in 2024, including both in-house and co-promoted products. 

Fexuclue, Korea’s 34th domestically developed new drug, continued its explosive trajectory, surging 47 percent year-over-year in sales to 78.8 billion won. The drug had already posted a staggering 315 percent jump in 2023 revenue, making it the fastest-growing prescription drug in Korea.

Envlo, the company’s SGLT2 inhibitor for diabetes, also posted a breakout year. The combined sales of Envlo and its combo therapy Envlomet surpassed the 10-billion-won mark for the first time, skyrocketing 261 percent to 12.3 billion won from 3.4 billion won in 2023.

Daewoong also strengthened its portfolio through co-promotion deals. The anticoagulant drug LIXIANA (edoxaban), co-promoted with Daiichi Sankyo, climbed 12 percent to 117.5 billion won, while hypertension treatments Sevikar (olmesartan medoxomil) and Sevikar HCT added 4 percent to reach 110.9 billion won. The Zemiglo (gemigliptin) diabetes franchise, co-promoted with LG Chem, expanded 6 percent to 152.5 billion won.